| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Mantle-Cell | 44 | 2022 | 713 | 10.440 |
Why?
|
| Multiple Myeloma | 61 | 2015 | 2138 | 4.670 |
Why?
|
| Pyrazines | 24 | 2019 | 495 | 3.440 |
Why?
|
| Thalidomide | 27 | 2017 | 569 | 2.990 |
Why?
|
| Boronic Acids | 22 | 2014 | 362 | 2.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2022 | 15862 | 2.130 |
Why?
|
| Pyrazoles | 8 | 2019 | 1471 | 1.890 |
Why?
|
| Oligopeptides | 9 | 2013 | 429 | 1.570 |
Why?
|
| Pyrimidines | 9 | 2019 | 3518 | 1.500 |
Why?
|
| Antineoplastic Agents | 36 | 2019 | 14289 | 1.450 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2019 | 4757 | 1.290 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2015 | 1756 | 1.280 |
Why?
|
| Dexamethasone | 20 | 2013 | 1450 | 1.270 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2018 | 1664 | 1.180 |
Why?
|
| Bortezomib | 22 | 2014 | 543 | 1.170 |
Why?
|
| Adenine | 10 | 2022 | 631 | 1.120 |
Why?
|
| Rituximab | 18 | 2022 | 1528 | 1.030 |
Why?
|
| Drug Resistance, Neoplasm | 20 | 2019 | 5178 | 0.980 |
Why?
|
| Apoptosis | 23 | 2019 | 7591 | 0.980 |
Why?
|
| Piperidines | 10 | 2022 | 1035 | 0.950 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 15 | 2014 | 864 | 0.910 |
Why?
|
| Benzamides | 2 | 2019 | 1832 | 0.900 |
Why?
|
| Spiro Compounds | 4 | 2011 | 58 | 0.860 |
Why?
|
| Recurrence | 18 | 2017 | 4758 | 0.830 |
Why?
|
| Lymphopenia | 2 | 2022 | 199 | 0.810 |
Why?
|
| Salvage Therapy | 8 | 2015 | 2054 | 0.790 |
Why?
|
| Mice, SCID | 16 | 2014 | 1869 | 0.780 |
Why?
|
| Cell Proliferation | 17 | 2019 | 7226 | 0.760 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2013 | 589 | 0.740 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2015 | 393 | 0.730 |
Why?
|
| Lymphoma, B-Cell | 7 | 2015 | 895 | 0.700 |
Why?
|
| Neutropenia | 6 | 2015 | 968 | 0.670 |
Why?
|
| Aged | 62 | 2020 | 70117 | 0.660 |
Why?
|
| Treatment Outcome | 42 | 2022 | 32848 | 0.660 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 846 | 0.660 |
Why?
|
| Middle Aged | 65 | 2022 | 86204 | 0.620 |
Why?
|
| Humans | 131 | 2022 | 261506 | 0.620 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 406 | 0.610 |
Why?
|
| Aged, 80 and over | 37 | 2019 | 29902 | 0.600 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2011 | 273 | 0.600 |
Why?
|
| Melphalan | 12 | 2015 | 834 | 0.600 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2019 | 10035 | 0.560 |
Why?
|
| Molecular Targeted Therapy | 4 | 2015 | 2330 | 0.540 |
Why?
|
| Drug Substitution | 2 | 2015 | 87 | 0.540 |
Why?
|
| Male | 69 | 2020 | 123000 | 0.530 |
Why?
|
| Maintenance Chemotherapy | 2 | 2015 | 202 | 0.530 |
Why?
|
| Cyclophosphamide | 13 | 2022 | 3001 | 0.510 |
Why?
|
| Antibodies, Monoclonal | 16 | 2013 | 4367 | 0.510 |
Why?
|
| B-Lymphocytes | 3 | 2019 | 1294 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 15 | 2013 | 6550 | 0.510 |
Why?
|
| Disease-Free Survival | 22 | 2015 | 10001 | 0.510 |
Why?
|
| Electroacupuncture | 1 | 2014 | 35 | 0.490 |
Why?
|
| Leukemia, B-Cell | 1 | 2015 | 117 | 0.480 |
Why?
|
| Drug Synergism | 10 | 2013 | 1313 | 0.480 |
Why?
|
| Disease Progression | 12 | 2019 | 6682 | 0.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2014 | 1039 | 0.470 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 210 | 0.470 |
Why?
|
| Lymphoma, Follicular | 4 | 2014 | 587 | 0.460 |
Why?
|
| Adult | 44 | 2022 | 77950 | 0.450 |
Why?
|
| Proteasome Inhibitors | 2 | 2013 | 231 | 0.440 |
Why?
|
| Doxorubicin | 12 | 2022 | 3005 | 0.440 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2015 | 6207 | 0.440 |
Why?
|
| Cell Line, Tumor | 28 | 2018 | 14551 | 0.440 |
Why?
|
| Female | 66 | 2019 | 141928 | 0.430 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2013 | 566 | 0.420 |
Why?
|
| Drug Discovery | 1 | 2015 | 324 | 0.420 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2018 | 923 | 0.420 |
Why?
|
| Vincristine | 10 | 2022 | 1511 | 0.410 |
Why?
|
| beta 2-Microglobulin | 5 | 2011 | 184 | 0.400 |
Why?
|
| Remission Induction | 9 | 2013 | 3569 | 0.390 |
Why?
|
| Immunosuppressive Agents | 3 | 2015 | 1375 | 0.380 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 3230 | 0.380 |
Why?
|
| Diarrhea | 4 | 2015 | 686 | 0.380 |
Why?
|
| Blotting, Western | 13 | 2014 | 3536 | 0.370 |
Why?
|
| Transplantation, Autologous | 12 | 2013 | 1914 | 0.360 |
Why?
|
| Sirolimus | 1 | 2014 | 814 | 0.350 |
Why?
|
| Fatigue | 5 | 2015 | 1239 | 0.340 |
Why?
|
| Methotrexate | 5 | 2022 | 999 | 0.340 |
Why?
|
| Survival Analysis | 10 | 2017 | 9180 | 0.340 |
Why?
|
| Sulfonamides | 1 | 2018 | 1823 | 0.340 |
Why?
|
| Animals | 34 | 2018 | 59536 | 0.330 |
Why?
|
| Signal Transduction | 11 | 2019 | 11965 | 0.330 |
Why?
|
| Acupuncture Therapy | 1 | 2009 | 89 | 0.320 |
Why?
|
| Hematologic Diseases | 4 | 2014 | 242 | 0.310 |
Why?
|
| Cyclin D1 | 2 | 2010 | 576 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 4938 | 0.310 |
Why?
|
| Drug Administration Schedule | 8 | 2015 | 3472 | 0.310 |
Why?
|
| Antigens, CD20 | 1 | 2008 | 206 | 0.300 |
Why?
|
| Time Factors | 10 | 2019 | 12926 | 0.300 |
Why?
|
| Blood Viscosity | 1 | 2007 | 23 | 0.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2009 | 749 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2013 | 1248 | 0.290 |
Why?
|
| Oncology Nursing | 1 | 2007 | 51 | 0.290 |
Why?
|
| Immunotherapy | 3 | 2009 | 3341 | 0.290 |
Why?
|
| Mice | 27 | 2018 | 34495 | 0.290 |
Why?
|
| Administration, Oral | 4 | 2015 | 1544 | 0.280 |
Why?
|
| Cytarabine | 5 | 2022 | 1973 | 0.280 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 120 | 0.260 |
Why?
|
| Myeloablative Agonists | 4 | 2015 | 384 | 0.260 |
Why?
|
| Transplantation Conditioning | 7 | 2015 | 2238 | 0.260 |
Why?
|
| Survival Rate | 13 | 2015 | 12221 | 0.260 |
Why?
|
| Mitochondria | 2 | 2013 | 1282 | 0.250 |
Why?
|
| In Vitro Techniques | 4 | 2011 | 1618 | 0.240 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 14889 | 0.240 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2010 | 216 | 0.220 |
Why?
|
| Deoxycytidine | 3 | 2013 | 1353 | 0.220 |
Why?
|
| Amyloidosis | 2 | 2015 | 176 | 0.220 |
Why?
|
| Stem Cell Transplantation | 4 | 2015 | 1360 | 0.220 |
Why?
|
| Composite Lymphoma | 2 | 2012 | 15 | 0.220 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2022 | 107 | 0.210 |
Why?
|
| SEER Program | 3 | 2011 | 1000 | 0.210 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7222 | 0.200 |
Why?
|
| Mice, Inbred NOD | 6 | 2014 | 905 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 1299 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 2594 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2018 | 3821 | 0.190 |
Why?
|
| Prodrugs | 1 | 2001 | 217 | 0.180 |
Why?
|
| Immunophenotyping | 5 | 2014 | 1681 | 0.180 |
Why?
|
| Reactive Oxygen Species | 3 | 2013 | 987 | 0.180 |
Why?
|
| Interleukin-6 | 4 | 2012 | 1038 | 0.170 |
Why?
|
| Testicular Neoplasms | 1 | 2002 | 529 | 0.160 |
Why?
|
| Age Distribution | 2 | 2011 | 698 | 0.160 |
Why?
|
| Oncogene Protein v-akt | 1 | 2018 | 101 | 0.160 |
Why?
|
| Retrospective Studies | 17 | 2015 | 37905 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1429 | 0.160 |
Why?
|
| Retreatment | 2 | 2015 | 452 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2011 | 709 | 0.150 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 666 | 0.150 |
Why?
|
| Pain | 3 | 2014 | 1658 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2014 | 8865 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 4988 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2009 | 621 | 0.150 |
Why?
|
| Immunologic Factors | 2 | 2013 | 649 | 0.140 |
Why?
|
| NF-kappa B | 3 | 2012 | 1549 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2018 | 1678 | 0.140 |
Why?
|
| Killer Cells, Natural | 2 | 2013 | 904 | 0.140 |
Why?
|
| Epistaxis | 1 | 2015 | 30 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2012 | 1489 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 130 | 0.130 |
Why?
|
| Macrophages | 2 | 2014 | 1304 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2014 | 109 | 0.130 |
Why?
|
| Thromboembolism | 1 | 2015 | 155 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 1443 | 0.120 |
Why?
|
| Lymphoma | 1 | 2002 | 1467 | 0.120 |
Why?
|
| Risk | 2 | 2015 | 1972 | 0.120 |
Why?
|
| Biological Factors | 1 | 2013 | 45 | 0.120 |
Why?
|
| Macrophage Activation | 1 | 2014 | 148 | 0.120 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 299 | 0.120 |
Why?
|
| Neoplasm Staging | 8 | 2014 | 13658 | 0.120 |
Why?
|
| Portraits as Topic | 1 | 2013 | 6 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2015 | 1391 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2013 | 3552 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 1656 | 0.120 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2013 | 57 | 0.120 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 94 | 0.110 |
Why?
|
| Plasma Cells | 2 | 2011 | 192 | 0.110 |
Why?
|
| Nausea | 1 | 2015 | 525 | 0.110 |
Why?
|
| Cancer Vaccines | 2 | 2009 | 697 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 8 | 2013 | 5395 | 0.110 |
Why?
|
| Acrylates | 1 | 2012 | 30 | 0.110 |
Why?
|
| Verapamil | 1 | 2012 | 78 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 284 | 0.110 |
Why?
|
| Monoterpenes | 1 | 2012 | 10 | 0.110 |
Why?
|
| Registries | 2 | 2011 | 2170 | 0.110 |
Why?
|
| DNA Damage | 2 | 2018 | 1954 | 0.110 |
Why?
|
| Comorbidity | 4 | 2014 | 2352 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 249 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2013 | 2864 | 0.110 |
Why?
|
| Dyspnea | 1 | 2015 | 416 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2009 | 142 | 0.100 |
Why?
|
| Ascorbic Acid | 2 | 2011 | 131 | 0.100 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2011 | 19 | 0.100 |
Why?
|
| Phosphorylation | 5 | 2013 | 4804 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2014 | 5319 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 486 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 242 | 0.100 |
Why?
|
| Gout Suppressants | 1 | 2011 | 21 | 0.100 |
Why?
|
| Oxides | 2 | 2011 | 211 | 0.100 |
Why?
|
| Incidence | 3 | 2012 | 5673 | 0.100 |
Why?
|
| Urate Oxidase | 1 | 2011 | 32 | 0.100 |
Why?
|
| Arsenicals | 2 | 2011 | 201 | 0.100 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2011 | 29 | 0.100 |
Why?
|
| Everolimus | 1 | 2014 | 415 | 0.100 |
Why?
|
| Transglutaminases | 1 | 2012 | 99 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 1493 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 4298 | 0.100 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2011 | 33 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2011 | 68 | 0.100 |
Why?
|
| Osteoblasts | 1 | 2014 | 370 | 0.100 |
Why?
|
| Karyopherins | 1 | 2012 | 136 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2014 | 2292 | 0.100 |
Why?
|
| Age Factors | 5 | 2014 | 5377 | 0.100 |
Why?
|
| Membrane Microdomains | 2 | 2011 | 80 | 0.100 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2010 | 10 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 219 | 0.100 |
Why?
|
| Protein Transport | 1 | 2013 | 734 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2013 | 675 | 0.100 |
Why?
|
| Cyclin D2 | 1 | 2010 | 40 | 0.100 |
Why?
|
| Cell Survival | 6 | 2014 | 3045 | 0.100 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 207 | 0.100 |
Why?
|
| Proteomics | 1 | 2018 | 1380 | 0.100 |
Why?
|
| Guanidines | 1 | 2010 | 60 | 0.090 |
Why?
|
| Jaundice, Obstructive | 1 | 2010 | 16 | 0.090 |
Why?
|
| Fetal Blood | 1 | 2013 | 482 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 347 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 419 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2012 | 321 | 0.090 |
Why?
|
| Interleukin-2 | 3 | 2013 | 842 | 0.090 |
Why?
|
| Filgrastim | 2 | 2009 | 191 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2011 | 235 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2012 | 298 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 8873 | 0.090 |
Why?
|
| United States | 4 | 2012 | 15433 | 0.090 |
Why?
|
| Metformin | 1 | 2014 | 378 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2010 | 447 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2014 | 953 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 347 | 0.090 |
Why?
|
| Diphtheria Toxin | 2 | 2007 | 81 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 167 | 0.090 |
Why?
|
| Drug Evaluation | 1 | 2010 | 425 | 0.090 |
Why?
|
| Models, Biological | 1 | 2019 | 3254 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 586 | 0.090 |
Why?
|
| Phenols | 1 | 2010 | 107 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 254 | 0.090 |
Why?
|
| Cell Cycle | 3 | 2010 | 2084 | 0.090 |
Why?
|
| Annexin A2 | 1 | 2009 | 15 | 0.090 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2009 | 26 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2012 | 2390 | 0.090 |
Why?
|
| Blood Cells | 1 | 2009 | 127 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 203 | 0.090 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2009 | 37 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 2014 | 1960 | 0.090 |
Why?
|
| Major Histocompatibility Complex | 1 | 2009 | 91 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 1082 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 589 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 1290 | 0.080 |
Why?
|
| Epitopes | 1 | 2011 | 685 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2015 | 732 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2010 | 397 | 0.080 |
Why?
|
| Insulin | 1 | 2014 | 1454 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 719 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2009 | 240 | 0.080 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 615 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2012 | 591 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2011 | 627 | 0.080 |
Why?
|
| Triazoles | 1 | 2012 | 617 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2009 | 1144 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 507 | 0.080 |
Why?
|
| Young Adult | 5 | 2014 | 21445 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 1 | 2008 | 139 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2013 | 1620 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 311 | 0.080 |
Why?
|
| Pneumonia | 1 | 2014 | 751 | 0.080 |
Why?
|
| Dendritic Cells | 3 | 2011 | 1085 | 0.080 |
Why?
|
| Caspases | 2 | 2007 | 661 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 266 | 0.080 |
Why?
|
| Placebos | 1 | 2008 | 437 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2013 | 5637 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 2 | 2012 | 1121 | 0.080 |
Why?
|
| Bone Transplantation | 1 | 2008 | 134 | 0.080 |
Why?
|
| Receptors, IgG | 1 | 2007 | 102 | 0.070 |
Why?
|
| Nursing Assessment | 1 | 2007 | 42 | 0.070 |
Why?
|
| Confusion | 1 | 2007 | 31 | 0.070 |
Why?
|
| Social Class | 1 | 2008 | 310 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1350 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 600 | 0.070 |
Why?
|
| Information Services | 1 | 2007 | 50 | 0.070 |
Why?
|
| HLA-A Antigens | 1 | 2007 | 102 | 0.070 |
Why?
|
| Nurse's Role | 1 | 2007 | 42 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2014 | 11538 | 0.070 |
Why?
|
| Bone Marrow Examination | 1 | 2007 | 153 | 0.070 |
Why?
|
| beta Catenin | 1 | 2010 | 688 | 0.070 |
Why?
|
| Prednisone | 3 | 2014 | 984 | 0.070 |
Why?
|
| Imidazoles | 1 | 2012 | 999 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2009 | 1385 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 321 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7551 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1016 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 327 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2014 | 2295 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 750 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 602 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 324 | 0.070 |
Why?
|
| Indoles | 1 | 2011 | 1009 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 703 | 0.070 |
Why?
|
| Vinblastine | 1 | 2006 | 453 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2008 | 291 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2006 | 143 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 2843 | 0.070 |
Why?
|
| Antioxidants | 1 | 2008 | 507 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 500 | 0.070 |
Why?
|
| Calcium | 1 | 2012 | 1537 | 0.070 |
Why?
|
| RNA | 1 | 2010 | 1013 | 0.070 |
Why?
|
| Bleomycin | 1 | 2006 | 467 | 0.070 |
Why?
|
| Peptides | 2 | 2011 | 1479 | 0.070 |
Why?
|
| Aorta | 1 | 2009 | 692 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2007 | 503 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 1519 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2007 | 245 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 369 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 1506 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 2927 | 0.060 |
Why?
|
| Mutation | 2 | 2014 | 15179 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2008 | 619 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2009 | 2358 | 0.060 |
Why?
|
| Autografts | 2 | 2015 | 165 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 485 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2001 | 4849 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 3719 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1547 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 527 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2007 | 629 | 0.060 |
Why?
|
| Texas | 1 | 2015 | 6311 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1362 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 650 | 0.060 |
Why?
|
| Prognosis | 8 | 2014 | 21713 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 1351 | 0.060 |
Why?
|
| Pain Management | 1 | 2009 | 668 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 2139 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1005 | 0.050 |
Why?
|
| Risk Factors | 3 | 2015 | 17523 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2012 | 9244 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2007 | 712 | 0.050 |
Why?
|
| Internet | 1 | 2007 | 706 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 5159 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 748 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 3639 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2010 | 5270 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2012 | 3033 | 0.050 |
Why?
|
| Liver | 1 | 2011 | 2961 | 0.050 |
Why?
|
| Colitis | 1 | 2004 | 340 | 0.050 |
Why?
|
| Biomarkers, Tumor | 3 | 2015 | 10331 | 0.050 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2014 | 278 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2007 | 899 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 635 | 0.050 |
Why?
|
| Taxoids | 1 | 2004 | 967 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2004 | 15694 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 2 | 2011 | 188 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 3890 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2011 | 342 | 0.050 |
Why?
|
| Capecitabine | 1 | 2001 | 388 | 0.050 |
Why?
|
| K562 Cells | 2 | 2013 | 338 | 0.050 |
Why?
|
| Genotype | 1 | 2008 | 4109 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 852 | 0.040 |
Why?
|
| Carcinoma, Embryonal | 1 | 1999 | 29 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2011 | 182 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2005 | 1555 | 0.040 |
Why?
|
| Fenretinide | 1 | 1999 | 96 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2012 | 1077 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 1165 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2014 | 2232 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 703 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 7548 | 0.040 |
Why?
|
| Antigens, CD19 | 2 | 2011 | 577 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 4821 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1999 | 365 | 0.040 |
Why?
|
| Graft Survival | 2 | 2012 | 1062 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2012 | 630 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2011 | 588 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2013 | 5710 | 0.040 |
Why?
|
| Translocation, Genetic | 2 | 2014 | 1245 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2001 | 1944 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 2054 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2013 | 12873 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 2403 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 3869 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 2216 | 0.030 |
Why?
|
| Transfection | 2 | 2010 | 2944 | 0.030 |
Why?
|
| Base Sequence | 2 | 2013 | 4917 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 1870 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 125 | 0.030 |
Why?
|
| Threonine | 1 | 2014 | 161 | 0.030 |
Why?
|
| Thiourea | 1 | 2013 | 18 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cell Tracking | 1 | 2014 | 38 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2013 | 22 | 0.030 |
Why?
|
| Methionine | 1 | 2014 | 159 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2013 | 47 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 166 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 113 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 83 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 2014 | 119 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2013 | 84 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 295 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 2314 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2014 | 388 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2013 | 93 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 47 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2013 | 314 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 358 | 0.030 |
Why?
|
| Perilla | 1 | 2012 | 2 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 3154 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 733 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 4744 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 626 | 0.030 |
Why?
|
| Primary Graft Dysfunction | 1 | 2012 | 34 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 168 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 343 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2011 | 51 | 0.030 |
Why?
|
| Uric Acid | 1 | 2011 | 75 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 247 | 0.030 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 351 | 0.020 |
Why?
|
| Wnt3 Protein | 1 | 2010 | 17 | 0.020 |
Why?
|
| Consolidation Chemotherapy | 1 | 2012 | 155 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2007 | 2588 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 37 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 663 | 0.020 |
Why?
|
| MafB Transcription Factor | 1 | 2010 | 12 | 0.020 |
Why?
|
| Casein Kinase Ialpha | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2013 | 652 | 0.020 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 62 | 0.020 |
Why?
|
| Wnt3A Protein | 1 | 2010 | 29 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 72 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 1399 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2009 | 1586 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 435 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 598 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 281 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 285 | 0.020 |
Why?
|
| Tretinoin | 1 | 2013 | 623 | 0.020 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2010 | 38 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2010 | 163 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 1555 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 1008 | 0.020 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 437 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 219 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 367 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 161 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 717 | 0.020 |
Why?
|
| Graft vs Host Disease | 2 | 2012 | 2638 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2009 | 20 | 0.020 |
Why?
|
| Topotecan | 1 | 2010 | 239 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2010 | 143 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2009 | 115 | 0.020 |
Why?
|
| Thromboplastin | 1 | 2009 | 34 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Quinazolines | 1 | 2014 | 923 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 134 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 502 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2011 | 271 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 168 | 0.020 |
Why?
|
| E-Selectin | 1 | 2009 | 103 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 392 | 0.020 |
Why?
|
| Brain | 1 | 2002 | 4113 | 0.020 |
Why?
|
| Benzylamines | 1 | 2009 | 105 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 310 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2009 | 121 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2007 | 4143 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2009 | 221 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2009 | 152 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2009 | 119 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 558 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 344 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 612 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 639 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 691 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2010 | 771 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2013 | 1046 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 531 | 0.020 |
Why?
|
| Hemagglutinins, Viral | 1 | 2006 | 45 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2013 | 1129 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 870 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 157 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2011 | 769 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2006 | 86 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 781 | 0.020 |
Why?
|
| Phospholipase C gamma | 1 | 2006 | 54 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2009 | 478 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 848 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2007 | 159 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3438 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 3842 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2007 | 272 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2171 | 0.020 |
Why?
|
| Influenza B virus | 1 | 2006 | 127 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2508 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2006 | 299 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 810 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 591 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 461 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2006 | 189 | 0.020 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2006 | 152 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 259 | 0.020 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2005 | 24 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 2803 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 2315 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 825 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 1021 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 301 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 191 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 2074 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 460 | 0.020 |
Why?
|
| DNA Repair | 1 | 2013 | 1872 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2006 | 355 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 7702 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3570 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 891 | 0.020 |
Why?
|
| Piperazines | 1 | 2013 | 2101 | 0.020 |
Why?
|
| Hypoalbuminemia | 1 | 2004 | 46 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2013 | 1589 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 186 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2006 | 242 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2004 | 170 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1033 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5112 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2004 | 170 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 32 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2006 | 435 | 0.010 |
Why?
|
| Stents | 1 | 2010 | 1096 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2006 | 478 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6150 | 0.010 |
Why?
|
| RNA Interference | 1 | 2007 | 1408 | 0.010 |
Why?
|
| Medicare | 1 | 2007 | 860 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1382 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 1031 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1764 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 6869 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 4549 | 0.010 |
Why?
|
| Proteins | 1 | 2009 | 1963 | 0.010 |
Why?
|
| Vaccination | 1 | 2007 | 1123 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 518 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 1904 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 1320 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 657 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 2055 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2013 | 2947 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 1999 | 85 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 4892 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 6942 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 1996 | 0.010 |
Why?
|
| Cell Death | 1 | 1999 | 671 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 2195 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 31252 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 6915 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1999 | 4078 | 0.000 |
Why?
|